Maria is a postdoctoral fellow from Madrid, Spain. During her PhD, she worked on understanding the aging mechanism in neutrophils and how the removal of these aged PMN by bone marrow macrophages triggers the homeostatic release of hematopoietic progenitors from the bone marrow into the blood. Now in her postdoctoral fellowship in Dr. Merad’s lab, she would like to address the fascinating question of how the peripheral nervous system modulates macrophage phenotype and functions during cancer progression.
Fundings : Human Frontiers Science Program
Assaf Magen, Ph.D. is a computational scientist (bioinformatics) developing computational strategies to mine single-cell genomics and multiplex imaging data of human malignancies. During his doctoral work, he identified novel subsets of immune cells and their prognostic value in murine and human tumors. He is currently working on characterizing the crosstalk between immune, malignant and stromal cells, and how their interactions may affect tumor development and patient response to therapy.
Maxime is a postdoctoral fellow who is part of both the Merad Lab and the Brown Lab. He is taking advantage of the Jedi mice (developed by the Brown laboratory) to study the mechanisms of cytotoxic CD8+ T cell (CTLs)-mediated tumor regression in vivo. He is particularly interested in the interactions between CTLs and cancer-initiating cells.
Fundings: Belgian American Education Foundation
Alfonso is a postdoctoral fellow from Madrid, Spain. During his PhD studies in the University of Navarra (Pamplona, Spain), he investigated the role type 1 conventional dendritic cells play in cancer immunity. In conjunction with Brian Brown’s lab, he is currently working on the development of novel myeloid cell-targeted therapies in the context of cancer immunotherapy.
Gurkan received his master’s degree in molecular biology and genetics from Koc University (Istanbul, Turkey) and his doctorate in oncological sciences from the University of Utah School of Medicine. He joined the Merad and the Brown labs at Mount Sinai to study the role of cancer genetics in tumor immunity. He is fascinated by the nature of the complex interactions between cancer cells and immune cells. He thinks that a better understanding of the incredibly dynamic co-evolution of cancer cells and the immune system will eventually make most cancers if not all manageable diseases.
Funding: The National Cancer Institute
Camille is an oncologist/hematologist. She completed her hematology advanced fellowship in 2015 and worked at Saint-Louis hospital and Institut Gustave Roussy (Paris, France) in departments with expertise in lymphoid malignancies. She is currently an MD – PhD student, focusing on the tumor microenvironment. She studies the immune mechanisms involved in patients prognostic and response to treatment.
Fundings: Fondation pour la Recherche Médicale
Humans evolved in presence of bacteria, viruses and parasites. Stefan studies how the immune system shapes the microbiota inhabiting our body, and how the microbiota shape the immune system. Understanding the underlying mechanisms might lead to new therapies for many diseases, including cancer.
Fundings: German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)
Jerome is a PharmD., PhD. clinical pathologist from Nantes (France). He focused his PhD on the study of IL-22BP, a natural inhibitor of IL-22, and identified it as an important regulator of gut inflammation, especially during inflammatory bowel disease (IBD). He now wants to extend his understanding of IBD inflammation by performing high dimensional analysis using scRNAseq and CyTOF to try to identify cellular and molecular patterns characterizing specific subgroups of patients encompassed within the main IBD phenotypes.
Fundings: Fondation Bettencourt-Schueller